ReviewAntioxidants (Basel, Switzerland)2021
Antioxidant Therapy in Inflammatory Bowel Diseases.
Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 83 citations in OpenAlex.
- Fibroblast-specificAmerican journal of physiology. Gastrointestinal and liver physiology · 2026Article
- Obesity-Related Oxidative Stress and Antioxidant Properties of Natural Compounds in the Enteric Nervous System: A Literature Overview.Antioxidants (Basel, Switzerland) · 2026Review
- CD73 Blockade Aggravate Dextran-Sodium-Sulfate-Induced Colitis via Down Regulating Inosine.Journal of inflammation research · 2026Article
- Ferroptosis in hematological malignancies: molecular mechanisms and therapeutic potential.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- The role of dietary factors in the prevention and management of inflammatory bowel disease: a comprehensive review.Nutrition & metabolism · 2025Review
- Therapeutic potential of alpha-lipoic acid on mitochondrial dynamics, oxidative/nitrosative stress, and histopathological changes in rat ulcerative colitis model.Inflammopharmacology · 2025Article
- Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions.RSC advances · 2025Review
- Pyodermatitis-Pyostomatitis Vegetans: The Role of Langerin Deficiency in Disease Pathogenesis.Journal of clinical medicine · 2025Article
- Method of oral delivery affects vitamin C-mediated alleviation of colitis in a mouse model.Gut microbes reports · 2025Article
- The emerging role of honeysuckle flower in inflammatory bowel disease.Frontiers in nutrition · 2025Review
- Aging and Intestinal Fibrosis: Mechanisms, Implications, and Therapeutic Strategies.Clinical interventions in aging · 2025Review
- Potential of nutraceuticals in celiac disease.Tissue barriers · 2025Review
- Protective Effects of Peanut Sprouts from a Smart Farming System on the Barrier Function of Human Epithelial Cells.Preventive nutrition and food science · 2024Article
- Novel Insight into the Composition Differences Between Buffalo and Holstein Milk and Potential Anti-Inflammation and Antioxidant Effect on Caco-2 Cells.Foods (Basel, Switzerland) · 2024Article
- The Composition, Antioxidant and Antibacterial Activity of Essential Oils from Five Species of the Magnoliaceae Family.Molecules (Basel, Switzerland) · 2024Article
- Modulatory Impact of Oxidative Stress on Action Potentials in Pathophysiological States: A Comprehensive Review.Antioxidants (Basel, Switzerland) · 2024Review
- Article
- Hydroethanolic Extract ofAntioxidants (Basel, Switzerland) · 2024Article
- The Role of the Gut Microbiome in Inflammatory Bowel Disease: The Middle East Perspective.Journal of personalized medicine · 2024Article
- Cotinus coggygria Scop. Attenuates Acetic Acid-Induced Colitis in Rats by Regulation of Inflammatory Mediators.Applied biochemistry and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD) are a group of chronic, incurable diseases of the digestive tract, the etiology of which remains unclear to this day. IBD result in significant repercussions on the quality of patients' life. There is a continuous increase in the incidence and prevalence of IBD worldwide, and it is becoming a significant public health burden. Pharmaceuticals commonly used in IBD management, for example, mesalamine, sulfasalazine, corticosteroids, and others, expose patients to diverse, potentially detrimental side effects and frequently do not provide sufficient disease control. The chronic inflammation underlies the etiology of IBD and closely associates with oxidative/nitrosative stress and a vast generation of reactive oxygen/nitrogen species. Relative to this, several substances with antioxidant and anti-inflammatory properties are now intensively researched as possible adjunctive or independent treatment options in IBD. Representatives of several different groups, including natural and chemical compounds will be characterized in this dissertation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.